ScholarLens Back to search
2010•China Medical HeraldRequires access

Clinical observation of Aripiprazole in the treatment of schizophrenia

Changqing Gao

Open publisher page 0 citations

Abstract

Objective:To explore the efficacy and safety of Aripiprazole in the treatment of schizophrenia. Methods:111 cases of patients with schizophrenia were randomly divided into Aripiprazole group (n=56) and Clozapine group (n=55). Positive and negative symptoms scale (PANSS) and treatment emergent symptom scale (TESS) were used to measure the efficacy and safety before treatment and treatment at the end of 1st,2nd,4th,6th and 8th week respectively. Results:There was no significant difference in efficacy between two groups (P0.05). However,significant differences were observed between two groups in the reduction rates of scales about cognitive factors and negative symptoms. Conclusion:Aripiprazole is a safe and effective agent in the treatment of schizophrenia.

About this research paper

What this paper is about

Objective:To explore the efficacy and safety of Aripiprazole in the treatment of schizophrenia. Methods:111 cases of patients with schizophrenia were randomly divided into Aripiprazole group (n=56) and Clozapine group (n=55). Positive and negative symptoms scale (PANSS) and treatment emergent symptom scale (TESS) were used to measure the efficacy and safety before treatment and treatment at the end of 1st,2nd,4th,6th and 8th week respectively. Results:There was no significant difference in efficacy between two groups (P0.05). However,significant differences were observed between two groups in the reduction rates of scales about cognitive factors and negative symptoms. Conclusion:Aripiprazole is a safe and effective agent in the treatment of schizophrenia.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective:To explore the efficacy and safety of Aripiprazole in the treatment of schizophrenia. Methods:111 cases of patients with schizophrenia were randomly divided into Aripiprazole group (n=56) and Clozapine group (n=55). Positive and negative symptoms scale (PANSS) and treatment emergent symptom scale (TESS) were used to measure the efficacy and safety before treatment and treatment at the end of 1st,2nd,4th,6th and 8th week respectively. Results:There was no significant difference in efficacy between two groups (P0.05). However,significant differences were observed between two groups in the reduction rates of scales about cognitive factors and negative symptoms. Conclusion:Aripiprazole is a safe and effective agent in the treatment of schizophrenia.

Key concepts: Aripiprazole, Medicine, Schizophrenia (object-oriented programming), Negative symptom, Clozapine, Clinical efficacy, Internal medicine, Positive and Negative Syndrome Scale

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Clinical observation of Aripiprazole in the treatment of schizophrenia — Research Paper | ScholarLens